Luc Dirix
- Oncology top 0.1%
- HER2/EGFR in Cancer Research 68
- Cancer Treatment and Pharmacology 56
- Cancer Cells and Metastasis 40
- Cancer Immunotherapy and Biomarkers 36
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies 51
- Cancer Genomics and Diagnostics 32
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 38
- Genetics top 1%
- Estrogen and related hormone effects 34
- Molecular Biology top 1%
- Co-authors
- Steven Van LaerePeter A. van DamPeter VermeulenIlse Van der AuweraCécile ColpaertEric A. Van MarckGert G. Van den EyndenEric Van Marck
- Journals
- Journal of Clinical Oncology (47 papers)Cancer Research (39 papers)Annals of Oncology (23 papers)
- Partner nations
- BelgiumUnited StatesUnited Kingdom
In The Last Decade
Luc Dirix
307 papers receiving 14.3k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Oncology 9.4k
- Cancer Research 4.6k
- Pulmonary and Respiratory Medicine 3.4k
- Genetics 739
- Molecular Biology 4.4k
Countries citing papers authored by Luc Dirix
This map shows the geographic impact of Luc Dirix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luc Dirix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luc Dirix more than expected).
Fields of papers citing papers by Luc Dirix
This network shows the impact of papers produced by Luc Dirix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luc Dirix. The network helps show where Luc Dirix may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Luc Dirix, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 4 | |
| 2 | 2022 | 15 | |
| 3 | 2022 | 4 | |
| 4 | 2021 | 44 | |
| 5 | 2020 | 52 | |
| 6 | 2019 | 34 | |
| 7 | 2019 | 9 | |
| 8 | 2017 | 70 | |
| 9 | 2014 | 110 | |
| 10 | 2013 | 34 | |
| 11 | 2013 | 302 | |
| 12 | 2013 | 59 | |
| 13 | 2011 | 46 | |
| 14 | 2010 | 331 | |
| 15 | Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer : Abstract #4120 | 2009 | 1 |
| 16 | 2008 | 23 | |
| 17 | 2008 | 24 | |
| 18 | 2008 | 228 | |
| 19 | Extended adjuvant letrozole following five years of tamoxifen is cost-effective from a Belgian health care payer's perspective | 2006 | 3 |
| 20 | 2005 | 48 |
About Luc Dirix
Luc Dirix is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 311 papers that have together received 14.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (68 papers), Cancer Treatment and Pharmacology (56 papers), Breast Cancer Treatment Studies (51 papers), Cancer Cells and Metastasis (40 papers), Advanced Breast Cancer Therapies (38 papers), Cancer Immunotherapy and Biomarkers (36 papers), Estrogen and related hormone effects (34 papers) and Cancer Genomics and Diagnostics (32 papers). The work is most often cited by research in Oncology (9.4k citations), Cancer Research (4.6k citations) and Pulmonary and Respiratory Medicine (3.4k citations). Luc Dirix has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Steven Van Laere, Peter A. van Dam, Peter Vermeulen, Peter Vermeulen, Ilse Van der Auwera, Cécile Colpaert, Eric A. Van Marck, Gert G. Van den Eynden, Eric Van Marck and Ina Benoy. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, British Journal of Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.